Abstract
Binding sites for the ETS domain family of transcription factors are found in the promoters of the matrix metalloproteinase (MMP) family of matrix degrading enzymes. Evidence is accumulating that both these groups of molecules are important in the process of angiogenesis in addition to matrix degradation. Furthermore, they are both expressed in tumor tissue as well as in the normal surrounding stroma. These factors along with various sites at which they may be regulated collectively makes them attractive targets to consider for therapeutic intervention in the processes of invasion and metastasis.
Current Drug Targets
Title: ETS Proteins and MMPs: Partners in Invasion and Metastasis
Volume: 3 Issue: 5
Author(s): Sadmeet Singh, Jane Barrett, Kenji Sakata, Richard G. Tozer and Gurmit Singh
Affiliation:
Abstract: Binding sites for the ETS domain family of transcription factors are found in the promoters of the matrix metalloproteinase (MMP) family of matrix degrading enzymes. Evidence is accumulating that both these groups of molecules are important in the process of angiogenesis in addition to matrix degradation. Furthermore, they are both expressed in tumor tissue as well as in the normal surrounding stroma. These factors along with various sites at which they may be regulated collectively makes them attractive targets to consider for therapeutic intervention in the processes of invasion and metastasis.
Export Options
About this article
Cite this article as:
Sadmeet Singh , Jane Barrett , Kenji Sakata , Richard G. Tozer and Gurmit Singh , ETS Proteins and MMPs: Partners in Invasion and Metastasis, Current Drug Targets 2002; 3 (5) . https://dx.doi.org/10.2174/1389450023347489
DOI https://dx.doi.org/10.2174/1389450023347489 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Multidrug Resistance Mechanisms and their Interactions with the Radiopharmaceutical Probes Used for an In Vivo Detection
Current Drug Metabolism Fabrication of Poly Hydroxybutyrate-Polyethylene Glycol-Folic Acid Nanoparticles Loaded by Paclitaxel
Current Drug Delivery Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Melanocortin Receptor Type 3 as a Potential Target for Anti-Inflammatory Therapy
Current Drug Targets - Inflammation & Allergy Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
Current Cancer Drug Targets Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Anti-cancer Therapies in High Grade Gliomas
Current Proteomics Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research